Celgene (CELG) Unit Reports Meaningful Improvements Observed in PALACE 1
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Moody's Boosts Outlook on Celgene (CELG) to Stable; Affirms Ratings
June 12, 2013 4:50 PM EDTMoody's Investors Service revised the outlook on Celgene Corporation (Nasdaq: CELG) to positive from stable. At the same time, Moody's affirmed Celgene's existing ratings including the Baa2 senior unsecured rating and the Prime-2 commercial paper rating.
Ratings affirmed:
Baa2 senior unsecured notes due 2015, 2020 and 2040
(P)Baa2 senior unsecured shelf registration
Prime-2 commercial paper rating
"Expanding use of Revlimid and pending approvals of Apremilast in psoriatic arthritis and Abraxane in pancreatic cancer should... More
